focus -WSS

focus

author：focus 2025-10-01 02:15:55 - browse：8471

Illumina building. -- biotech coverage from STAT — Adobe

LONDON — The European Union on Wednesday issued an antitrust fine of $475 million to the U.S. genetic sequencing giant Illumina for closing its acquisition of cancer detection company Grail before clearing it with regulators.

The fine amounts to nearly 10% of Illumina’s annual global revenue, which is the most the European Commission can penalize a company under its merger regulations. The commission called Illumina’s actions “an unprecedented and very serious infringement” of the EU’s policies, including the “cornerstone” that regulators review deals that can alter the market.

The commission also issued what it called a symbolic fine of 1,000 Euros, or about $1,100, to Grail for what it said was the firm’s “active role” in the deal’s infringement of EU rules.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Researchers explore possible ties between long Covid, menopause

focus

explore

WSS

STAT Summit: Michael J. Fox on progress in Parkinson's research

Opioid cravings were reduced by anti

Researchers tackle phage therapy hurdles for wider adoption

First Opinion Podcast: Long Covid needs a new approach

Reporting on presidential health from Reagan to Trump and Biden

STAT Summit: Biotech founders on deal

entertainment

focus

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

Solve the antibiotic resistance crisis with preventive drugs

New air purifier tech could be key to improving indoor air quality

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Affirmative action in medical school literally saved lives

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Activists slam private health insurers over coverage restrictions

A new drug could help frostbite victims avoid its ravages

Novavax promises a turnaround & Lilly roils the obesity market

Solve the antibiotic resistance crisis with preventive drugs

hotspot

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

In 'major milestone,' FDA approves first cell therapy for solid tumors

Ukraine seeks to reclaim its role as a hub for clinical trials

The EU Joint Clinical Assessment needs to live up to its promise

CEOs share strategies for surviving biotech slump

Obamacare plans could cover weight loss drugs

knowledge

focus

explore

explore